The 36-month beta value for GBIO is also noteworthy at 2.81. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for GBIO is 48.76M, and at present, short sellers hold a 4.11% of that float. The average trading volume of GBIO on October 11, 2024 was 104.73K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GBIO) stock’s latest price update
Generation Bio Co (NASDAQ: GBIO) has experienced a decline in its stock price by -6.25 compared to its previous closing price of 2.40. However, the company has seen a fall of -5.46% in its stock price over the last five trading days. globenewswire.com reported 2024-09-12 that CAMBRIDGE, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) — Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 10:20 a.m. ET in New York.
GBIO’s Market Performance
Generation Bio Co (GBIO) has experienced a -5.46% fall in stock performance for the past week, with a -7.79% drop in the past month, and a -17.58% drop in the past quarter. The volatility ratio for the week is 7.25%, and the volatility levels for the past 30 days are at 9.67% for GBIO. The simple moving average for the past 20 days is -10.36% for GBIO’s stock, with a -17.25% simple moving average for the past 200 days.
Analysts’ Opinion of GBIO
Canaccord Genuity, on the other hand, stated in their research note that they expect to see GBIO reach a price target of $9. The rating they have provided for GBIO stocks is “Buy” according to the report published on November 08th, 2022.
GBIO Trading at -10.39% from the 50-Day Moving Average
After a stumble in the market that brought GBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.61% of loss for the given period.
Volatility was left at 9.67%, however, over the last 30 days, the volatility rate increased by 7.25%, as shares sank -11.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.63% lower at present.
During the last 5 trading sessions, GBIO fell by -5.46%, which changed the moving average for the period of 200-days by +17.80% in comparison to the 20-day moving average, which settled at $2.51. In addition, Generation Bio Co saw 36.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GBIO starting from Paone Antoinette, who sale 6,719 shares at the price of $2.74 back on Jul 01 ’24. After this action, Paone Antoinette now owns 13,807 shares of Generation Bio Co, valued at $18,410 using the latest closing price.
Paone Antoinette, the CHIEF OPERATING OFFICER of Generation Bio Co, sale 2,445 shares at $1.62 during a trade that took place back on Jan 02 ’24, which means that Paone Antoinette is holding 5,828 shares at $3,961 based on the most recent closing price.
Stock Fundamentals for GBIO
Current profitability levels for the company are sitting at:
- -8.49 for the present operating margin
- 0.56 for the gross margin
The net margin for Generation Bio Co stands at -12.03. The total capital return value is set at -0.48. Equity return is now at value -85.71, with -47.28 for asset returns.
Based on Generation Bio Co (GBIO), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at -1.1. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is -6.97.
Currently, EBITDA for the company is -133.3 million with net debt to EBITDA at -0.61. When we switch over and look at the enterprise to sales, we see a ratio of 16.37. The receivables turnover for the company is 9.85for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.42.
Conclusion
In summary, Generation Bio Co (GBIO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
